VTGN
VTGN
NASDAQ · Biotechnology

Vistagen Therapeutics Inc

$0.18
+0.00 (+0.34%)
Financial Highlights (FY 2026)
Revenue
1.58M
Net Income
-86,807,396
Gross Margin
—
Profit Margin
-5,491.3%
Rev Growth
—
D/E Ratio
0.00
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin — — 37.6% 37.6%
Operating Margin -5,683.7% -10,365.4% 26.4% 28.6%
Profit Margin -5,491.3% -10,050.9% 22.0% 24.2%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 1.58M 848.4K 9.03M 9.73M
Gross Profit — — 3.40M 3.66M
Operating Income -89,765,414 -87,942,529 2.39M 2.78M
Net Income -86,807,396 -80,993,442 1.99M 2.35M
Gross Margin — — 37.6% 37.6%
Operating Margin -5,683.7% -10,365.4% 26.4% 28.6%
Profit Margin -5,491.3% -10,050.9% 22.0% 24.2%
Rev Growth — -24.1% +1.4% +15.7%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 10.5K 0 10.09M 8.64M
Total Equity 3.87M — 16.52M 14.60M
D/E Ratio 0.00 — 0.61 0.59
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -89,596,160 -92,813,868 3.04M 3.38M
Free Cash Flow — — 1.40M 2.01M